BR0308431A - Parecoxib sódico cristalino - Google Patents
Parecoxib sódico cristalinoInfo
- Publication number
- BR0308431A BR0308431A BR0308431-0A BR0308431A BR0308431A BR 0308431 A BR0308431 A BR 0308431A BR 0308431 A BR0308431 A BR 0308431A BR 0308431 A BR0308431 A BR 0308431A
- Authority
- BR
- Brazil
- Prior art keywords
- parecoxib
- unsolvated
- slurry
- crystalline
- parecoxib sodium
- Prior art date
Links
- 229960004662 parecoxib Drugs 0.000 title abstract 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- 229960003925 parecoxib sodium Drugs 0.000 abstract 3
- 239000002002 slurry Substances 0.000 abstract 3
- ICJGKYTXBRDUMV-UHFFFAOYSA-N trichloro(6-trichlorosilylhexyl)silane Chemical compound Cl[Si](Cl)(Cl)CCCCCC[Si](Cl)(Cl)Cl ICJGKYTXBRDUMV-UHFFFAOYSA-N 0.000 abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"PARECOXIB SóDICO CRISTALINO". A presente invenção refere-se a parecoxib sódico em uma forma cristalina que é substancialmente anidra e substancialmente não-solvatada . Várias de tais formas cristalinas anidras não-solvatadas foram agora identificadas, incluindo as formas A, B e E conforme aqui descrito. é também proporcionada uma substância de droga parecoxib sódico em que pelo menos cerca de 90% do parecoxib sódico está em uma ou mais formas cristalinas anidras não-solvatadas. Uma tal substância de droga é um intermediário estável no armazenamento que pode ser ainda processado, por exemplo por dissolução ou feitura de uma pasta fluida em um meio aquoso em conjunto com um ou mais excipientes parentericamente aceitáveis, seguido por liofilização da solução ou pasta fluida resultante para proporcionar uma composição injetável reconstituível adequada para uso terapêutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36456702P | 2002-03-15 | 2002-03-15 | |
| US41798702P | 2002-10-11 | 2002-10-11 | |
| PCT/US2003/007484 WO2003078408A1 (en) | 2002-03-15 | 2003-03-12 | Crystalline parecoxib sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308431A true BR0308431A (pt) | 2005-01-18 |
Family
ID=28045416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308431-0A BR0308431A (pt) | 2002-03-15 | 2003-03-12 | Parecoxib sódico cristalino |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20030232871A1 (pt) |
| EP (1) | EP1485362A1 (pt) |
| JP (1) | JP2005529084A (pt) |
| KR (1) | KR100763045B1 (pt) |
| CN (1) | CN1642926A (pt) |
| AR (1) | AR038985A1 (pt) |
| AU (1) | AU2003220180A1 (pt) |
| BR (1) | BR0308431A (pt) |
| CA (1) | CA2478500A1 (pt) |
| CO (1) | CO5631437A2 (pt) |
| IL (1) | IL163780A0 (pt) |
| MX (1) | MXPA04008932A (pt) |
| MY (1) | MY148518A (pt) |
| NZ (1) | NZ535951A (pt) |
| PL (1) | PL372880A1 (pt) |
| RU (1) | RU2300529C2 (pt) |
| TW (1) | TW200400949A (pt) |
| WO (1) | WO2003078408A1 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003238669A1 (en) * | 2003-04-04 | 2004-10-25 | Hetero Drugs Limited | Novel crystalline forms of parecoxib sodium |
| US7268109B2 (en) | 2003-10-02 | 2007-09-11 | Elan Pharmaceuticals, Inc. | Method for reducing pain |
| WO2005065684A1 (en) * | 2003-12-24 | 2005-07-21 | Pharmacia Corporation | Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever |
| ITMI20040019A1 (it) * | 2004-01-12 | 2004-04-12 | Univ Bari | Derivati isossazolici e loro impiego come inibitori della ciclossigenasi |
| US7796785B2 (en) * | 2005-03-03 | 2010-09-14 | Fujifilm Corporation | Image extracting apparatus, image extracting method, and image extracting program |
| US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| US7989450B2 (en) | 2008-01-11 | 2011-08-02 | Universita' Degli Studi Di Bari | Functionalized diarylisoxazoles inhibitors of ciclooxygenase |
| GB0919757D0 (en) * | 2009-11-12 | 2009-12-30 | Johnson Matthey Plc | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| US8299295B2 (en) | 2009-10-15 | 2012-10-30 | Johnson Matthey Public Limited Company | Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| CN105726496B (zh) * | 2014-12-12 | 2019-05-28 | 湖南科伦药物研究有限公司 | 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品 |
| CN105125506A (zh) * | 2015-08-18 | 2015-12-09 | 上海秀新臣邦医药科技有限公司 | 一种注射用帕瑞昔布钠及其制备方法 |
| CN106692079A (zh) * | 2016-12-26 | 2017-05-24 | 上药东英（江苏）药业有限公司 | 一种帕瑞昔布钠长效冻干粉针制剂 |
| CN106580893A (zh) * | 2016-12-26 | 2017-04-26 | 上药东英（江苏）药业有限公司 | 一种帕瑞昔布钠冻干粉针制剂 |
| CN117003769B (zh) * | 2023-07-11 | 2024-11-22 | 中国科学院宁波材料技术与工程研究所 | 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE233743T1 (de) * | 1996-04-12 | 2003-03-15 | Searle & Co | N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren |
| EP1977749A1 (en) * | 1996-10-15 | 2008-10-08 | G.D. Searle LLC | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| MY137736A (en) * | 2001-04-03 | 2009-03-31 | Pharmacia Corp | Reconstitutable parenteral composition |
| MXPA04003072A (es) * | 2001-10-02 | 2004-09-06 | Pharmacia Corp | Procedimiento para preparar compuestos de bencenosulfonilo. |
-
2003
- 2003-03-12 AU AU2003220180A patent/AU2003220180A1/en not_active Abandoned
- 2003-03-12 JP JP2003576414A patent/JP2005529084A/ja active Pending
- 2003-03-12 BR BR0308431-0A patent/BR0308431A/pt not_active IP Right Cessation
- 2003-03-12 KR KR1020047014454A patent/KR100763045B1/ko not_active Expired - Fee Related
- 2003-03-12 PL PL03372880A patent/PL372880A1/xx not_active Application Discontinuation
- 2003-03-12 EP EP03716476A patent/EP1485362A1/en not_active Withdrawn
- 2003-03-12 IL IL16378003A patent/IL163780A0/xx unknown
- 2003-03-12 MX MXPA04008932A patent/MXPA04008932A/es unknown
- 2003-03-12 NZ NZ535951A patent/NZ535951A/en unknown
- 2003-03-12 CA CA002478500A patent/CA2478500A1/en not_active Abandoned
- 2003-03-12 US US10/387,173 patent/US20030232871A1/en not_active Abandoned
- 2003-03-12 RU RU2004127585/04A patent/RU2300529C2/ru not_active IP Right Cessation
- 2003-03-12 CN CNA038060884A patent/CN1642926A/zh active Pending
- 2003-03-12 WO PCT/US2003/007484 patent/WO2003078408A1/en not_active Ceased
- 2003-03-14 MY MYPI20030900A patent/MY148518A/en unknown
- 2003-03-14 TW TW092105693A patent/TW200400949A/zh unknown
- 2003-03-14 AR ARP030100915A patent/AR038985A1/es unknown
-
2004
- 2004-09-10 CO CO04090186A patent/CO5631437A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030232871A1 (en) | 2003-12-18 |
| CO5631437A2 (es) | 2006-04-28 |
| MXPA04008932A (es) | 2004-11-26 |
| AU2003220180A1 (en) | 2003-09-29 |
| RU2004127585A (ru) | 2005-04-10 |
| KR20040095288A (ko) | 2004-11-12 |
| AR038985A1 (es) | 2005-02-02 |
| RU2300529C2 (ru) | 2007-06-10 |
| CN1642926A (zh) | 2005-07-20 |
| EP1485362A1 (en) | 2004-12-15 |
| TW200400949A (en) | 2004-01-16 |
| NZ535951A (en) | 2006-02-24 |
| JP2005529084A (ja) | 2005-09-29 |
| CA2478500A1 (en) | 2003-09-25 |
| PL372880A1 (en) | 2005-08-08 |
| KR100763045B1 (ko) | 2007-10-04 |
| MY148518A (en) | 2013-04-30 |
| WO2003078408A1 (en) | 2003-09-25 |
| IL163780A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308431A (pt) | Parecoxib sódico cristalino | |
| AR109995A2 (es) | Método para inhibir la resorción ósea | |
| AR014886A1 (es) | 4,5-diarilimidazoles 2-substituidos, composiciones farmaceuticas que los contienen y su uso para la manufactura de medicamentos | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| BRPI0415639A (pt) | formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia | |
| ES2173948T3 (es) | Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral. | |
| SG151254A1 (en) | Substituted morpholine and thiomorpholine derivatives | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| BR0317463A (pt) | Métodos de triar para um composto que evita ou reduz a dissolução de um tetrâmero de transtiretina e de tratar uma doença amilóide transtiretina | |
| AR022076A1 (es) | Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| BR0308212A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| NO20022201L (no) | Lösninger inneholdende Epinastin | |
| UY27852A1 (es) | Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| BR112021018169A2 (pt) | Composto para o controle de diabetes de felinos | |
| PE20211199A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR9908301A (pt) | Derivados de indol e composições farmacêuticas que compreendem os mesmos | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| MXPA02012730A (es) | Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide. | |
| NO20021160L (no) | Bestanddeler | |
| BR0008657A (pt) | Comprimidos deglutìveis com teor elevado den-acetilcisteì na e processo para a preparação dosmesmos | |
| BRPI0508392A (pt) | materiais e métodos para tratar distúrbios de coagulação | |
| BRPI0518785A2 (pt) | composto de anel de 7 membros e mÉtodo de produÇço e aplicaÇço farmacÊutica do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES. |